AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.65-1.86 (-1.76%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.65-1.86 (-1.76%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|
10.4 C
New York
Monday, November 2, 2026

Tag: cause

newsFORsourcecompanycontentinformationreleases1market

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Second Quarter of 2025

TAIPEI, Aug. 5, 2025 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results...

Sandstorm Gold Royalties Supports Royal Gold’s Acquisition of Kansanshi Gold Stream

VANCOUVER, BC, Aug. 5, 2025 /CNW/ - Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm" or the "Company") (NYSE: SAND) (TSX: SSL) today acknowledges and...

Sandstorm Gold Royalties Supports Royal Gold’s Acquisition of Kansanshi Gold Stream

VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ - Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm" or the "Company") (NYSE: SAND) (TSX: SSL) today acknowledges and...

Weekly progress on share repurchase program to cover share plans and reduce capital

Press Release

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

   
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

Minim Martap Development Update

Highlights

Why XentaFlex Is Emerging as 2025’s Most Affordable, Simplest, and Most Effective Joint Pain Solution

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex 
More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex

Velocity Trader Exposes Wall Street’s Hidden Friday Price Strategy Used to Trigger Short-Term Market Wins

Jim Fink Investing’s Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities. 
Jim Fink Investing’s Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities.

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market

WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.

Group 1 Automotive Acquires High Volume Luxury Brand Dealership

Expected to Generate $210 Million in Annual RevenuesHOUSTON, Aug. 4, 2025 /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 250...

BLADEX ANNOUNCES 2Q25 NET PROFIT OF $64.2 MILLION, OR $1.73 PER SHARE, RESULTING IN AN ANNUALIZED RETURN ON EQUITY OF 18.5%

PANAMA CITY, Aug. 4, 2025 /PRNewswire/ -- Banco Latinoamericano de Comercio Exterior, S.A. (NYSE: BLX, "Bladex", or "the Bank"), a Panama-based multinational bank originally established...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCause

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers